Neurocrine Biosciences (NBIX) management has been clear that they want to reinvest the company’s growing financial resources into expanding the clinical pipeline and, eventually, the business. This has been more than just talk, with multiple deals (Idorsia, Xenon (XENE), Voyager (VYGR), Jnana) since October of 2018 that have meaningfully expanded the company’s pipeline and R&D efforts.
The latest announcement, a multi-drug R&D partnership with Takeda (TAK), is more of the same, with this partnership adding more than a half-dozen potential drugs in new therapeutic